Optimizing ribavirin dosage: A new challenge to improve treatment efficacy in genotype 1 hepatitis C patients

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 6-7, 2009, Pages 580-583

  Loustaud Ratti, V ^a   Stanke Labesque, F ^b   Marquet, P ^c   Gagnieu, M C ^d   Maynard, M ^d   Babany, G ^e   Trepo C ^d  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e Roche   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; GENOTYPE; HALF LIFE TIME; HEPATITIS C; HUMAN; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD;

ANEMIA; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RIBAVIRIN;

EID: 67649491088     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.04.009     Document Type: Article

References (24)

1. Bronowicki J.P., Ouzan D., Asselah T., Desmorat H., Zarski J.P., Foucher J., et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131 (2006) 1040-1048
2. Marcellin P. L'hépatite C en 2007 « Des progrès. Peut-on mieux faire... ». Gastroenterol Clin Biol 31 (2007) 3-6
3. Lindahl K., Stahle L., Bruchfeld A., and Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41 (2005) 275-279
4. Bruchfeld A., Lindahl K., Schvarcz R., and Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 24 (2002) 701-708
5. Glue P., Schenker S., Gupta S., Clement R.P., Zambas D., and Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol 49 (2000) 417-421
6. Wade J.R., Snoeck E., Duff F., Lamb M., and Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 62 (2006) 710-714
7. Jen J., Laughlin M., Chung C., Heft S., Affrime M.B., Gupta S.K., et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 72 (2002) 349-361
8. Larrat S., Stanke-Labesque F., Plages A., Zarski J.P., Bessard G., and Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 47 (2003) 124-129
9. Crespo M., Pou L., Esteban J.I., Falcó V., Ribera E., Lopez R., et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther 12 (2007) 1217-1223
10. Loustaud-Ratti V., Alain S., Rousseau A., Hubert I.F., Sauvage F.L., Marquet P., et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 47 (2008) 1453-1461
11. Dixit N.M., and Perelson A.S. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 63 (2006) 832-842
12. Maynard M., Pradat P., Gagnieu M.C., Souvignet C., and Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 13 (2008) 607-611
13. Dahari H., Markatou M., Zeremski M., Haller I., Ribeiro R.M., Licholai T., et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 47 (2007) 23-30
14. Donnerer J., Grahovac M., Stelzl E., Kessler H.H., Bankuti C., Stadlbauer V., et al. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology 76 (2006) 136-140
15. Rendón A.L., Núñez M., Romero M., Barreiro P., Martín-Carbonero L., García-Samaniego J., et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 39 (2005) 401-405
16. Nicot F., Legrand-Abravanel F., Lafont T., Dubois M., Sauné K., Pasquier C., et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 80 (2008) 1523-1529
17. Christensen P.B., Alsio A.A., Buhl M.R., Farkkila M., Morch K., Sangfelt P., et al. Ribavirin concentration at W4 is an independent predictor for sustained virological response after treatment of hepatitis C genotype 2/3 (Nordynamic trial) [abstract]. J Hepatol 48 Suppl 2 (2008) S6-S7
18. Jen J.F., Glue P., Gupta S., Zambas D., and Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 22 (2000) 555-565
19. Arase Y., Ikeda K., Tsubota A., Suzuki F., Suzuki Y., Saitoh S., et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 48 (2005) 138-144
20. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
21. Asahina Y., Izumi N., Enomoto N., Uchihara M., Kurosaki M., Onuki Y., et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43 (2005) 623-629
22. Feld J.J., Nanda S., Huang Y., Chen W., Cam M., Pusek S.N., et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46 (2007) 1548-1563
23. Bosch M.E., Sánchez A.J., Rojas F.S., and Ojeda C.B. Ribavirin: analytical determinations since the origin until today. J Pharm Biomed Anal 45 (2007) 185-193
24. Dusheiko G.M., Hezode C., Pol S., Goeser T., Bronowicki J.P., Bourliere M., et al. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon alfa 2A with or without ribavirin: further interim analysis. Results of the Prove 2 study [abstract]. J Hepatol 48 Suppl. 2 (2008) S26